DocuSign Envelope ID: C5C5FBAD-BABC-41E0-AA56-8F91E3A3C942

Carbon Reduction PlanSupplier name: Moderna Biotech Distributor UK Limited
Publication date: March 2024
Commitment to achieving Net Zero
Moderna Biotech Distributor UK Ltd (“Moderna UK Distributor”), acting together with its affiliated entity, Moderna Biotech Manufacturing UK Ltd (“Moderna UK Manufacturing,” and together, “Moderna UK”), each of which is an indirect subsidiary of ModernaTX, Inc., is committed to achieving Net Zero emissions by 2050.

Baseline Emissions Footprint
Baseline emissions are a record of the greenhouse gases that have been produced in thepast and were produced prior to the introduction of any strategies to reduce emissions.
Baseline emissions are the reference point against which emissions reduction can bemeasured.
Baseline Year: 2021
Additional Details relating to the Baseline Emissions calculations.
For the purposes of this initial Plan, Moderna UK Distributor will use a baseline year of 2021,
which reflects emissions of its predecessor entity, Moderna Biotech UK Limited. Baseline year
2021 was selected to align with ModernaTX, Inc.’s global baseline year accounting andreporting.
In baseline year 2021, carbon emissions within Moderna UK’s operational boundary werepredominately associated with value chain operations (i.e., Scope 3 categories for upstream
transportation & distribution and downstream transportation & distribution). Moderna UK did nothave appreciable source of emissions from assets under our direct operational control (i.e.,Scopes 1 & 2 emissions), nor appreciable emissions from employee commuting or businesstravel (Scope 3 emissions).
Increases in emissions from expanded operations of Moderna UK (including operations of its
predecessor entity, Moderna Biotech UK Limited) in 2022 are included in the “Current Emissions
Reporting” Section of this Plan.

DocuSign Envelope ID: C5C5FBAD-BABC-41E0-AA56-8F91E3A3C942

Baseline year emissions: 2021
EMISSIONSTOTAL (tCO2e)

Scope 10 metric tons

Scope 20 metric tons

Scope 3108 metric tons

(Included Sources)

Upstream Transportation & Distribution
Waste Generated in Operations
Business Travel
Employee Commuting
Downstream Transportation & Distribution

Total Emissions

108 metric tons

Current Emissions Reporting
Reporting Year: 2022
NOTE: As of the publication date of this Carbon Reduction Plan, Moderna UK’s current reporting
year is 2022, reflecting operations of Moderna UK Distributor (including operations of its
predecessor entity, Moderna Biotech UK Limited) and Moderna UK Manufacturing. Future
updates to this Carbon Reduction Plan will be completed within 6 months of our financial yearend.
Additional Details relating to the Current Emissions calculations.
In reporting year 2022, Moderna UK expanded staffing levels for our United Kingdom operations.
Expansion activities in 2022 resulted in new emissions from employee commuting (Scope 3) andbusiness travel (Scope 3).
EMISSIONSTOTAL (tCO2e)

Scope 10 metric tons

Scope 20 metric tons

Scope 3504 metric tons

(Included Sources)

Upstream Transportation & Distribution
Waste Generated in Operations
Business Travel
Employee Commuting
Downstream Transportation & Distribution

Total Emissions

504 metric tons

DocuSign Envelope ID: C5C5FBAD-BABC-41E0-AA56-8F91E3A3C942

Emissions reduction targets
In 2023, Moderna restructured its activities in the UK to conduct business primarily throughModerna UK Distributor (for commercial and medical affairs activities) and Moderna UK
Manufacturing (for manufacturing and research & development activities). Moderna UKManufacturing commenced construction of the Moderna Innovation and Technology Centre(MITC) in Harwell, UK. The MITC development will encompass a research, development andmanufacturing facility, providing the UK public with access to cutting-edge mRNA vaccines fora wide range of respiratory diseases, pending regulatory assessment and licensure.
Pharmaceutical products manufactured by Moderna UK Manufacturing at MITC are expected
to be commercialized and sold by Moderna UK Distributor as the supplier under procurement
tenders. Completion of the MITC is anticipated in 2025.
The Moderna Innovation and Technology Centre is designed to significantly reduce emissions
that are typically associated with biotech manufacturing processes. Design features include
the efficient use of a small manufacturing footprint to reduce energy demands from heating,ventilation and air condition systems and the installation of heat pumps for building heating,cooling and domestic hot water production. These design elements and technologies will
reduce consumption of fossil fuels and the generation of associated emissions.
For emissions attributed to the generation of purchased electricity, it is our intent to obtain
Renewable Energy Guarantees of Origin to cover 100 percent of electricity purchased.
For applicable Scope 3 categories (i.e., upstream transportation and distribution, waste
generated in operations, business travel, employee commuting, and downstream
transportation and distribution), we expect emissions to increase in the near-term as we scale
up operations, and then decrease as we implement carbon reduction projects and engage
with value chain partners ahead of 2050.

Carbon Reduction Projects
In-progress and future carbon reduction projects



Installation of four pipe heat pump system for simultaneous heating and cooling (forthe space heating and cooling)
Installation of heat pump water heaters for domestic hot water production
Installation of kitchen hood control system for demand-based exhaust air flow
Installation of energy efficient LED lighting
Installation of electric vehicle charging stations
U.S. Green Buildings Council’s Leadership in Energy and Environmental Design(LEED) Certification
Engagement with value chain partners to reduce Scope 3 emissions.

DocuSign Envelope ID: C5C5FBAD-BABC-41E0-AA56-8F91E3A3C942

Declaration and Sign OffThis Carbon Reduction Plan has been completed in accordance with PPN 06/21 andassociated guidance and reporting standard for Carbon Reduction Plans.
Emissions have been reported and recorded in accordance with the published reporting
standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard1
and uses the appropriate Government emission conversion factors for greenhouse gas
company reporting2.
Scope 1 and Scope 2 emissions have been reported in accordance with SECR
requirements, and the required subset of Scope 3 emissions have been reported inaccordance with the published reporting standard for Carbon Reduction Plans and theCorporate Value Chain (Scope 3) Standard3.
This Carbon Reduction Plan has been reviewed and signed off by the board of directors (orequivalent management body).

Signed on behalf of the Supplier (Moderna Biotech Distributor UK Ltd):____________________________________________________
Brian Sandstrom
Director, Moderna Biotech Distributor UK Limited
Date:

19 March 2024

Signed on behalf of Moderna Biotech Manufacturing UK Ltd:____________________________________________________
Brian Sandstrom
Director, Moderna Biotech Manufacturing UK Limited
Date:119 March 2024

https://ghgprotocol.org/corporate-standard
https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting3
https://ghgprotocol.org/standards/scope-3-standard
2